Short answer
AtriCure, Inc. (ATRC) filed an 8-K current report with the SEC on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results released for quarter ended September 30, 2026.
AtriCure, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results released for quarter ended September 30, 2026
- Conference call scheduled November 3, 2026 at 4:30 p.m. Eastern Time
- Investor focus: Exhibit 99.1 contains the detailed results and management commentary
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $154.5M, up 15.0% year over year, led by U.S. growth of 17.1% to $128.0M
- Profitability inflection: net income $4.1M versus $0.3M loss, adjusted EBITDA $26.8M, up 51%
- Gross margin expanded 180 basis points to 77.3%, driven by favorable product and geographic mix
- Minimally invasive ablation declined as physicians adopted PFA catheters, highlighting competitive procedure-mix risk
- 2026 guidance: revenue $606M-$610M, adjusted EBITDA $91M-$94M, adjusted EPS $0.40-$0.46
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other AtriCure, Inc. 8-K filings
Get the next ATRC 8-K as it lands
Follow ATRC for push alerts, or ask the research agent what this filing means.